title: Uveal Melanoma Cell Lines: Where do they come from? (An American Ophthalmological Society Thesis).
abstract: OBJECTIVE
  To determine whether some of the most often used uveal melanoma cell lines resemble their original tumor.
  
  
  METHODS
  Analysis of the literature, patient charts, histopathology, mutations, chromosome status, HLA type, and expression of melanocyte markers on cell lines and their primary tumors. We examined five cell lines and the primary tumors from which they were derived.
  
  
  RESULTS
  Four of the five examined primary tumors were unusual: one occupied the orbit, two were recurrences after prior irradiation, and one developed in an eye with a nevus of Ota. One cell line did not contain the GNA11 mutation, but it was present in the primary tumor. Three of the primary tumors had monosomy 3 (two of these lacked BAP1 expression); however, all five cell lines showed disomy 3 and BAP1 expression. All of the cell lines had gain of 8q. Two cell lines lacked expression of melanocyte markers, although these were present in the corresponding primary tumor.
  
  
  CONCLUSIONS
  All cell lines could be traced back to their original uveal melanoma. Four of the five primary tumors were unusual. Cell lines often differed from their primary tumor in chromosome status and melanocyte markers. However, their specific chromosome aberrations and capacity to continue proliferation characterize them as uveal melanoma cell lines.
authors.affiliation: Department of Ophthalmology, Leiden University Medical Center, Leiden, The Netherlands (Dr Jager); Schepens Eye Research Institute, Massachusetts Eye and Ear, Harvard Medical School, Boston, Massachusetts (Dr Jager, Dr Ksander); Florida Lions Ocular Pathology Laboratory, Bascom Palmer Eye Institute, University of Miami, Miami, Florida (Dr Magner, Dr Dubovy); and Instituto de Oftalmologia Conde de Valenciana, Mexico City, Mexico (Dr Magner).
authors.forename: Martine J
authors.initials: MJ
authors.lastname: Jager
authors.affiliation: Department of Ophthalmology, Leiden University Medical Center, Leiden, The Netherlands (Dr Jager); Schepens Eye Research Institute, Massachusetts Eye and Ear, Harvard Medical School, Boston, Massachusetts (Dr Jager, Dr Ksander); Florida Lions Ocular Pathology Laboratory, Bascom Palmer Eye Institute, University of Miami, Miami, Florida (Dr Magner, Dr Dubovy); and Instituto de Oftalmologia Conde de Valenciana, Mexico City, Mexico (Dr Magner).
authors.forename: J Antonio Bermudez
authors.initials: JA
authors.lastname: Magner
authors.affiliation: Department of Ophthalmology, Leiden University Medical Center, Leiden, The Netherlands (Dr Jager); Schepens Eye Research Institute, Massachusetts Eye and Ear, Harvard Medical School, Boston, Massachusetts (Dr Jager, Dr Ksander); Florida Lions Ocular Pathology Laboratory, Bascom Palmer Eye Institute, University of Miami, Miami, Florida (Dr Magner, Dr Dubovy); and Instituto de Oftalmologia Conde de Valenciana, Mexico City, Mexico (Dr Magner).
authors.forename: Bruce R
authors.initials: BR
authors.lastname: Ksander
authors.affiliation: Department of Ophthalmology, Leiden University Medical Center, Leiden, The Netherlands (Dr Jager); Schepens Eye Research Institute, Massachusetts Eye and Ear, Harvard Medical School, Boston, Massachusetts (Dr Jager, Dr Ksander); Florida Lions Ocular Pathology Laboratory, Bascom Palmer Eye Institute, University of Miami, Miami, Florida (Dr Magner, Dr Dubovy); and Instituto de Oftalmologia Conde de Valenciana, Mexico City, Mexico (Dr Magner).
authors.forename: Sander R
authors.initials: SR
authors.lastname: Dubovy
mesh_terms: D045744:Cell Line, Tumor; D006801:Humans; D008544:Melanocytes / Q000473:pathology*; D008545:Melanoma / Q000473:pathology*; D009885:Ophthalmology; D012955:Societies, Medical; D014481:United States; D014604:Uveal Neoplasms / Q000473:pathology*; D000098943:Uveal Melanoma